AstraZeneca and partner Daiichi Sankyo have unveiled a major change of plan for the first filing of their closely-watched lung cancer therapy datopotamab deruxtecan (Dato- DXd).
The companies filed Dato-DXd with the US Food and Drug Administration for patients with advanced or metastatic nonsquamous non-small cell...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?